MTD vs NAGE: fair value comparison
Mettler-Toledo International Inc. and Niagen Bioscience, Inc. · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, MTD currently sits closer to the top of our discount ranking. NAGE carries the stronger quality grade.
| MTD | NAGE | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $1,293.52 | $3.13 |
| 12-month range | $1,183.57–$1,468.09 | $3.13–$7.89 |
| Sector rank | #44 of 113 Healthcare | #47 of 113 Healthcare |
| Quality grade | C | A |
| Leverage | High | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Strong |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | — | Downtrend |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: MTD fair value analysis · NAGE fair value analysis